Home > Insider Trading > Filing (0001415889-13-000016)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1374328	Bond Laboratories Inc.	BNLB.OB	Medicinal Chemicals & Botanical Products (2833)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1497703	S John Wilson	4509 S. 143Rd Street Suite 1 Omaha NE 68137	Chief Executive Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2012-12-28	1,050,564	$0.00	3,699,570	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Option	$0.10	2011-06-08	2021-06-08	500,000	500,000	Direct
Common Stock	Warrant	$0.15	2008-12-31	2013-12-31	1,000,000	1,000,000	Direct
Common Stock	Stock Option	$0.09	2012-04-13	2017-04-13	500,000	500,000	Direct
Common Stock	Series C Convertible Preferred Stock	$0.25			668,000	17	Direct
Common Stock	Warrant	$0.30		2015-11-15	332,500	332,500	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2021-06-08	500,000	500,000	Direct
2013-12-31	1,000,000	1,000,000	Direct
2017-04-13	500,000	500,000	Direct
	668,000	17	Direct
2015-11-15	332,500	332,500	Direct

Footnotes

The Reporting Person acquired the shares of the Issuer's common stock ("Common Stock") for aggregate consideration of $12,500 in a privately negotiated transaction.
The Certificate of Designations, Preferences and Rights of the Series C Convertible Preferred Stock ("Series C Preferred") contains a provision preventing the conversion of the Series C Preferred if, as a result of such conversion, the Reporting Person would beneficially own, together with all other shares of Common Stock beneficially owned by the Reporting Person, in excess of 4.99% of the Issuer's Common Stock issued and outstanding.
The Series C Preferred are perpetual.
Each share of Series C Preferred is convertible into that number of shares of the Issuer's Common Stock equal to the quotient obtained by dividing $10,000 per share (the liquidation preference) by the conversion price then in effect, or $0.25 on the date of this Report. Conversion of the Series C Preferred is subject to the limitation on conversion described in Note 2.
The Warrant contains a provision preventing the exercise of the Warrant if, as a result of such exercise, the Reporting Person would beneficially own, together with all other shares of Common Stock beneficially owned by the Reporting Person, in excess of 9.99% of the Issuer's Common Stock issued and outstanding.